ELAN (Elanco Animal Health) COGS-to-Revenue : 0.43 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health COGS-to-Revenue?

Elanco Animal Health's Cost of Goods Sold for the three months ended in Mar. 2025 was $509 Mil. Its Revenue for the three months ended in Mar. 2025 was $1,193 Mil.

Elanco Animal Health's COGS to Revenue for the three months ended in Mar. 2025 was 0.43.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Elanco Animal Health's Gross Margin % for the three months ended in Mar. 2025 was 57.33%.

Elanco Animal Health COGS-to-Revenue Historical Data

The historical data trend for Elanco Animal Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health COGS-to-Revenue Chart

Elanco Animal Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.51

0.45

0.43

0.44

0.45

Elanco Animal Health Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.43	0.42	0.48	0.49	0.43

Elanco Animal Health COGS-to-Revenue Calculation

Elanco Animal Health's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2003	/	4439
	=	0.45

Elanco Animal Health's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	509	/	1193
	=	0.43

Elanco Animal Health (NYSE:ELAN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Elanco Animal Health's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	509 / 1193
	=	57.33 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Elanco Animal Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanco Animal Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

5EA:Germany

Address

2500 Innovation Way, Greenfield, IN, USA, 46140

Website

https://www.elanco.com

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Executives

Lawrence Erik Kurzius	director	18 LOVETON CIRCLE, SPARKS MD 21152
R David Hoover	director	C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Michael J Harrington	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jeffrey N Simmons	director, officer: Pres., Chief Executive Officer	2500 INNOVATION WAY, GREENFIELD IN 46140
William F Doyle	director
Grace Mcardle	officer: EVP, MANUFACTURING AND QUALITY	2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington	officer: See remarks	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
John P Bilbrey	director
Rajeev A. Modi	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen	director	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brabander Ellen De	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger	officer: Ex VP, Gen Counsel & Corp Sec	C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia	director	11690 N.W. 105TH STREET, MIAMI FL 33178
Uncas Gp Llc	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Gp Llc	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019